NAMS news

NewAmsterdam Pharma received European Commission approval for Ubeslo and Evlarco, marking the first regulatory approval of its drug obicetrapib. The update also reported strategic clinical progress and strong cash reserves, signaling potential market expansion in lipid management.

NewAmsterdam Pharma began a Phase 2b trial of obicetrapib for preclinical Alzheimer's, shifting focus beyond cardiovascular indications.

NewAmsterdam Pharma reported strong Q2 results including a positive European regulatory opinion for obicetrapib, signaling significant progress for its late-stage CVD pipeline.

NewAmsterdam and Menarini received a positive CHMP opinion patent dosing options for obicetrapib, pending further regulatory review.

NewAmsterdam Pharma Company N.V. has adopted an Employee Stock Purchase Plan (ESPP) authorizing up to 1,150,000 shares for eligible employees under IRC Section 423. The plan allows the board flexibility to create sub-plans for international employees while maintaining tax-qualified status.